Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Splicing Molecule Delays Leukemic Infiltration in CLL, Has Targeted Therapy Potential

September 17th 2021

H3B-8800, a splicing molecule that binds to Splicing Factor 3b Subunit 1, has been shown to delay leukemic infiltration in a model of chronic lymphocytic leukemia using NOD-SCID interleukin-2 receptor gamma mice.

Pirtobrutinib Offers a Potential Strategy to Overcome BTK Inhibitor Resistance in CLL

September 17th 2021

Catherine Callaghan Coombs, MD, discusses the rationale for the BRUIN study, key efficacy and safety findings, and next steps with pirtobrutinib in chronic lymphocytic leukemia.

Acalabrutinib Demonstrates Improved Tolerability, Similar Efficacy to Ibrutinib in CLL

September 15th 2021

John C. Byrd, MD, discusses key findings from ELEVATE-RR, differences between acalabrutinib and ibrutinib, and future directions with the second-generation inhibitor.

Dr. Danilov on the Need to Identify Novel Pathways in CLL

September 11th 2021

Alexey V. Danilov, MD, PhD, discusses the need to identify novel pathways for targeted therapy in chronic lymphocytic leukemia.

Noncovalent BTK Inhibitors, CAR T-Cell Therapy Generate Excitement in CLL

September 9th 2021

Sitting at the forefront of clinical development, pirtobrutinib and lisocabtagene maraleucel have generated significant enthusiasm in chronic lymphocytic leukemia.

Controlling Infections Could Be Key to Improving Survival in CLL

September 9th 2021

Patients with chronic lymphocytic leukemia are at an increased risk for infection whether they are in the premalignant state of monoclonal B lymphocytosis, during active surveillance for those are treatment naïve, or are on active treatment.

Pirtobrutinib Shows Impressive Efficacy in Previously Treated CLL/SLL

September 9th 2021

Pirtobrutinib, showcased promising efficacy signals across dose levels in previously treated patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Dr. Coombs on the Efficacy Results of the BRUIN Study With Pirtobrutinib in CLL

September 9th 2021

Catherine Callaghan Coombs, MD, discusses the efficacy results of the ongoing phase 1/2 BRUIN study with pirtobrutinib in chronic lymphocytic leukemia.

Dr. Danilov on the Utility of BTK Inhibitors in CLL

September 8th 2021

Alexey V. Danilov, MD, PhD, discusses the utility of BTK inhibitors as a treatment option for patients with chronic lymphocytic leukemia.

CLL: Final Thoughts

September 7th 2021

An expert panel provides their final thoughts about the future of the chronic lymphocytic leukemia (CLL) treatment landscape.

Emerging Agents for R/R CLL

September 7th 2021

Experts discuss emerging agents for the treatment of relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).

Dr. Atallah on the Prognostic Role of Undetectable MRD in CLL

August 31st 2021

Ehab L. Atallah, MD, discusses the prognostic role of undetectable minimal residual disease in chronic lymphocytic leukemia.

PI3K inhibitors for R/R CLL

August 31st 2021

An overview of data for PI3K inhibitors for in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).

CLL: Venetoclax in the R/R Setting

August 31st 2021

Experts in chronic lymphocytic leukemia (CLL) discuss retreating patients with venetoclax.

Emerging Strategies in the Management of Relapsed/Refractory CLL

August 30th 2021

Considerations for the future treatment landscape of relapsed/refractory CLL, in light of emerging practices and clinical trial data.

Therapeutic Sequencing Strategies in Relapsed/Refractory CLL

August 30th 2021

Experts detail optimal sequencing strategies when patients with relapsed/refractory CLL move on to the next line of therapy.

Key Clinical Data in Relapsed/Refractory CLL

August 30th 2021

An in-depth analysis of current therapeutic options in relapsed/refractory chronic lymphocytic leukemia.

High-Risk Patients With R/R CLL

August 24th 2021

A discussion about treatment for high-risk patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).

CLL: BTK Inhibitors in the R/R Setting

August 24th 2021

Nicole Lamanna, MD, provides an overview of Bruton's tyrosine kinase (BTK) inhibitors for chronic lymphocytic leukemia (CLL) in the relapsed/refractory (R/R) setting.

Frontline Therapy for CLL: Emerging Agents and Approaches

August 23rd 2021

Key opinion leaders look forward to upcoming improvements in the frontline management of chronic lymphocytic leukemia.